IL6 and cancer: Immunomodulatory CAFs (iCAFs) show a characteristic expression of proinflammatory cytokines (IL1B, IL6), chemokines (CXCR2 ligands) and immunomodulating molecules (IDO1) and, thus, seem to be analog to the previously described iCAFs in other cancer types (Figs. 3B, 6A, B)37.